Toxic multinodular goiter epidemiology and demographics

Revision as of 16:13, 6 October 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Toxic multinodular goiter Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic multinodular goiter from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Toxic multinodular goiter epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic multinodular goiter epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic multinodular goiter epidemiology and demographics

CDC on Toxic multinodular goiter epidemiology and demographics

Toxic multinodular goiter epidemiology and demographics in the news

Blogs on Toxic multinodular goiter epidemiology and demographics

Directions to Hospitals Treating Toxic multinodular goiter

Risk calculators and risk factors for Toxic multinodular goiter epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence of solitary toxic adenomas was 4.8 per 100,000 population per year.[1]
  • The incidence of toxic adenomas may be related to the degree of iodine sufficiency.
  • Correction of mild iodine deficiency has beneficial effects on the incidence of hyperthyroidism The total incidence of hyperthyroidism declined steadily to reach 44% of the control level in 1988/89. This was due to a decrease mostly of toxic nodular goiter.

Prevalence

  • the prevalence of toxic adenomas was 1.6% of 2846 thyrotoxic patients in a research done in Cleveland.
  • The prevalence of toxic thyroid nodules was significantly higher in an iodine-deficient population when compared with an iodine-sufficient population.

Case-fatality rate

Age

  • The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
  • Thyrotoxicosis associated with an autonomous nodule occurred in 57% of patients aged more than 60 years, whereas 13% of those younger than 60 years were hyperthyroid.

Race

In a recent study, the incidence of malignancy in TMG was found to be 7% and most of them were papillary microcarcinomas.[2]

Gender

  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
  • was noted to be higher specifically in females aged 50 years or older.[3]
  • Toxic nodules were seen in women six times more than in men.
  • All benign thyroid disorders showed predominance in women. Male/female ratio was 1/10 (10%) in the TMG group and 6/12 (50%) in the NMG group in our study. We also found a significant difference in the incidence of malignancy in male patients between the two groups and the incidence of malignancy was found to be higher in the non-toxic male patients.

Region

  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
  • Chiefly because of the iodination of table salt in the United States, the iodine intake of 200 to 600 μg/day in the United States is significantly higher than the nearly borderline deficient intake of 25 to 100 μg/day in many areas of Europe.
  • A higher incidence is seen in European countries in comparison with the United States. A general survey of six countries in Europe in 1986 revealed that 9% of thyrotoxic patients had autonomous nodules. In Malmo, Sweden, the mean annual incidence of thyrotoxicosis rose in 1988 to 1990 compared with the incidence in 1970 to 1974.

Developed Countries

References

  1. Siegel RD, Lee SL (1998). "Toxic nodular goiter. Toxic adenoma and toxic multinodular goiter". Endocrinol Metab Clin North Am. 27 (1): 151–68. PMID 9534034.
  2. Ríos A, Rodríguez JM, Balsalobre MD, Torregrosa NM, Tebar FJ, Parrilla P (2005). "Results of surgery for toxic multinodular goiter". Surg Today. 35 (11): 901–6. doi:10.1007/s00595-004-3051-7. PMID 16249841.
  3. Pelizzo MR, Bernante P, Toniato A, Fassina A (1997). "Frequency of thyroid carcinoma in a recent series of 539 consecutive thyroidectomies for multinodular goiter". Tumori. 83 (3): 653–5. PMID 9267482.

Template:WH Template:WS